1. Home
  2. ULY vs APVO Comparison

ULY vs APVO Comparison

Compare ULY & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Urgent.ly Inc.

ULY

Urgent.ly Inc.

HOLD

Current Price

$2.29

Market Cap

4.0M

Sector

N/A

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$1.36

Market Cap

21.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ULY
APVO
Founded
2013
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0M
21.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ULY
APVO
Price
$2.29
$1.36
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$11.50
N/A
AVG Volume (30 Days)
41.2K
633.3K
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$127,932,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$18.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.74
$1.04
52 Week High
$17.99
$298.00

Technical Indicators

Market Signals
Indicator
ULY
APVO
Relative Strength Index (RSI) 49.99 48.61
Support Level $1.75 $1.26
Resistance Level $1.93 $1.41
Average True Range (ATR) 0.16 0.09
MACD 0.05 0.02
Stochastic Oscillator 52.69 80.52

Price Performance

Historical Comparison
ULY
APVO

About ULY Urgent.ly Inc.

Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: